Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mallinckrodt Plc (MNK)

Mallinckrodt Plc (MNK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 437,284
  • Shares Outstanding, K 84,093
  • Annual Sales, $ 3,216 M
  • Annual Income, $ -3,607,000 K
  • 60-Month Beta 2.59
  • Price/Sales 0.14
  • Price/Cash Flow 0.28
  • Price/Book 0.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 2.05
  • Number of Estimates 8
  • High Estimate 2.11
  • Low Estimate 1.95
  • Prior Year 2.18
  • Growth Rate Est. (year over year) -5.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.03 +71.62%
on 01/08/20
5.75 -9.57%
on 01/16/20
+1.58 (+43.65%)
since 12/17/19
3-Month
2.39 +117.57%
on 10/21/19
5.75 -9.57%
on 01/16/20
+2.65 (+103.92%)
since 10/17/19
52-Week
1.43 +263.64%
on 09/05/19
27.33 -80.97%
on 02/26/19
-14.70 (-73.87%)
since 01/17/19

Most Recent Stories

More News
Mallinckrodt Shares Up 75.3% Since SmarTrend's Buy Recommendation (MNK)

SmarTrend identified an Uptrend for Mallinckrodt (NYSE:MNK) on October 23rd, 2019 at $2.99. In approximately 3 months, Mallinckrodt has returned 75.25% as of today's recent price of $5.24.

MNK : 5.20 (-0.76%)
SmarTrend Watching for Potential Pullback in Shares of Mallinckrodt After 6.48% Gain

Mallinckrodt (NYSE:MNK) traded in a range yesterday that spanned from a low of $3.28 to a high of $3.54. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $3.37...

MNK : 5.20 (-0.76%)
Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

AGN : 192.68 (-0.59%)
ENDP : 6.04 (-2.27%)
TEVA : 10.20 (-3.95%)
MNK : 5.20 (-0.76%)
Will J&J be Able to Overcome Its Legal Troubles in 2020?

Here we discuss the growth potential of J&J's (JNJ) stock in 2020.

JNJ : 149.17 (+0.65%)
ENDP : 6.04 (-2.27%)
TEVA : 10.20 (-3.95%)
MNK : 5.20 (-0.76%)
After Yesterday's Decline of 2.67%, Mallinckrodt Offers Investors Better Value

Mallinckrodt (NYSE:MNK) traded in a range yesterday that spanned from a low of $3.45 to a high of $3.58. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $3.55 on...

MNK : 5.20 (-0.76%)
Mallinckrodt to Present at the 38th Annual J.P. Morgan Healthcare Conference

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that Mark Trudeau, President and Chief Executive Officer, and other members of management will represent the company at...

JPM : 138.20 (+0.69%)
MNK : 5.20 (-0.76%)
Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis

Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.

ALKS : 19.24 (-3.75%)
INVA : 14.43 (-0.55%)
ANIK : 45.43 (-3.57%)
MNK : 5.20 (-0.76%)
First Patient Enrolled in Mallinckrodt Phase 4 Trial of Acthar® Gel (Repository Corticotropin Injection) for Severe Keratitis

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4, multi-center, multiple-dose, open-label study to assess the effects...

MNK : 5.20 (-0.76%)
Implied Volatility Surging for Mallinckrodt (MNK) Stock Options

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

MNK : 5.20 (-0.76%)
Mallinckrodt Announces Plans to Update Its Incentive Compensation Clawback Policy and Create Opioid Report

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced plans to update Mallinckrodt's Incentive Compensation Clawback Policy and to develop and publish a report on the Board's...

MNK : 5.20 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MNK with:

Business Summary

Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media...

See More

Key Turning Points

2nd Resistance Point 5.57
1st Resistance Point 5.38
Last Price 5.20
1st Support Level 4.96
2nd Support Level 4.73

See More

52-Week High 27.33
Fibonacci 61.8% 17.44
Fibonacci 50% 14.38
Fibonacci 38.2% 11.32
Last Price 5.20
52-Week Low 1.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar